LAMC1 Gene Pelvic Organ Prolapse Genetic Test
Test Name: LAMC1 Gene Pelvic Organ Prolapse LAMC1 Related Genetic Test
Components: Blood or Extracted DNA or One drop Blood on FTA Card
Price: 4400.0 AED
Report Delivery: 3 to 4 Weeks
Method: NGS Technology
Test Type: Dysmorphology
Doctor: Pediatrics
Test Department: Genetics
Pre Test Information: Clinical History of Patient who is going for LAMC1 Gene Pelvic Organ Prolapse, LAMC1 Related NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with LAMC1 Gene Pelvic Organ Prolapse, LAMC1 Related NGS Genetic DNA Test gene LAMC1.
Test Details
The LAMC1 gene is a gene that provides instructions for making a protein called laminin subunit gamma-1. This protein is a component of laminin, which is a protein complex that helps form the structure and stability of basement membranes in various tissues.
Pelvic organ prolapse (POP) is a condition where one or more organs in the pelvic region, such as the uterus, bladder, or rectum, descend or protrude into the vaginal canal. It is a common condition among women, especially those who have given birth or experienced menopause.
LAMC1-related NGS genetic testing refers to next-generation sequencing (NGS) tests that specifically analyze the LAMC1 gene for any genetic variations or mutations that may be associated with an increased risk of developing pelvic organ prolapse. These tests can help identify individuals who may be at a higher risk of developing the condition, allowing for early intervention and management.
It’s important to note that while genetic testing can provide valuable information about an individual’s genetic predisposition to certain conditions, it does not guarantee the development or absence of the condition. Environmental factors, lifestyle choices, and other genetic and non-genetic factors also play a role in the development of pelvic organ prolapse. Therefore, genetic testing should be used in conjunction with other clinical assessments and evaluations for a comprehensive understanding of an individual’s risk profile.
Test Name | LAMC1 Gene Pelvic organ prolapse LAMC1 related Genetic Test |
---|---|
Components | |
Price | 4400.0 AED |
Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
Report Delivery | 3 to 4 Weeks |
Method | NGS Technology |
Test type | Dysmorphology |
Doctor | Pediatrics |
Test Department: | Genetics |
Pre Test Information | Clinical History of Patient who is going for LAMC1 Gene Pelvic organ prolapse, LAMC1 related NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with LAMC1 Gene Pelvic organ prolapse, LAMC1 related NGS Genetic DNA Test gene LAMC1 |
Test Details |
The LAMC1 gene is a gene that provides instructions for making a protein called laminin subunit gamma-1. This protein is a component of laminin, which is a protein complex that helps form the structure and stability of basement membranes in various tissues. Pelvic organ prolapse (POP) is a condition where one or more organs in the pelvic region, such as the uterus, bladder, or rectum, descend or protrude into the vaginal canal. It is a common condition among women, especially those who have given birth or experienced menopause. LAMC1-related NGS genetic testing refers to next-generation sequencing (NGS) tests that specifically analyze the LAMC1 gene for any genetic variations or mutations that may be associated with an increased risk of developing pelvic organ prolapse. These tests can help identify individuals who may be at a higher risk of developing the condition, allowing for early intervention and management. It’s important to note that while genetic testing can provide valuable information about an individual’s genetic predisposition to certain conditions, it does not guarantee the development or absence of the condition. Environmental factors, lifestyle choices, and other genetic and non-genetic factors also play a role in the development of pelvic organ prolapse. Therefore, genetic testing should be used in conjunction with other clinical assessments and evaluations for a comprehensive understanding of an individual’s risk profile. |